肿瘤坏死因子-α抑制剂的使用与恶性肿瘤风险：一项系统评价和患者水平的荟萃分析。
Tumor Necrosis Factor-Alpha Inhibitor Use and Malignancy Risk: A Systematic Review and Patient Level Meta-Analysis.
作者信息
Driscoll Conor B, Rich Jordan M, Isaacson Dylan, Nicolas Joseph, Jiang Yu, Mi Xinlei, Yang Christopher, Kocsuta Victoria, Goh Regine, Patel Niti, Li Eric, Siddiqui Mohammad Rashid, Meyers Travis, Witte John S, Kachuri Linda, Zhang Hui, Beestrum Molly, Silberman Philip, Schaeffer Edward M, Kundu Shilajit D
机构信息
Department of Urology, Northwestern University Feinberg School of Medicine, 676 North St Clair Street, Suite 2300, Chicago, IL 60611, USA.
Department of Epidemiology and Population Health, Stanford University, 300 Pasteur Drive, Stanford, CA 94305, USA.
出版信息
Cancers (Basel). 2025 Jan 24;17(3):390. doi: 10.3390/cancers17030390.
Abstract
Over the last two decades, tumor necrosis factor-alpha inhibitors (TNF-Is) have become standard therapies for chronic inflammatory disorders, with an ongoing expansion of indications and off-label applications [...].
摘要
在过去二十年中，肿瘤坏死因子-α抑制剂（TNF-Is）已成为慢性炎症性疾病的标准疗法，其适应症和非适应症应用正在不断扩大[...]。
相似文献
1
Tumor Necrosis Factor-Alpha Inhibitor Use and Malignancy Risk: A Systematic Review and Patient Level Meta-Analysis.
Cancers (Basel). 2025 Jan 24;17(3):390. doi: 10.3390/cancers17030390.
2
TNF-alpha inhibitors for ankylosing spondylitis.
Cochrane Database Syst Rev. 2015 Apr 18;2015(4):CD005468. doi: 10.1002/14651858.CD005468.pub2.
3
The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials.
Am J Med. 2014 Dec;127(12):1208-32. doi: 10.1016/j.amjmed.2014.06.012. Epub 2014 Jun 17.
4
Conducting a real-world study of Tumor Necrosis factor-alpha inhibitors-induced Systemic Lupus Erythematosus based on the FAERS database.
Sci Rep. 2025 Feb 26;15(1):6838. doi: 10.1038/s41598-025-90566-3.
5
TNF inhibition for ophthalmic indications: current status and outlook.
BioDrugs. 2013 Aug;27(4):347-57. doi: 10.1007/s40259-013-0022-9.
6
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. doi: 10.3310/hta10420.
7
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
8
The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials.
J Am Acad Dermatol. 2011 Jun;64(6):1035-50. doi: 10.1016/j.jaad.2010.09.734. Epub 2011 Feb 18.
9
The Risk of Adverse Effects of TNF-α Inhibitors in Patients With Rheumatoid Arthritis: A Network Meta-Analysis.
Front Immunol. 2022 Feb 16;13:814429. doi: 10.3389/fimmu.2022.814429. eCollection 2022.
10
Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal.
Pharmacoeconomics. 2013 May;31(5):415-25. doi: 10.1007/s40273-013-0049-2.
本文引用的文献
1
A Multidisciplinary Approach to Patients with Psoriasis and a History of Malignancies or On-Treatment for Solid Tumors: A Narrative Literature Review.
Int J Mol Sci. 2023 Dec 16;24(24):17540. doi: 10.3390/ijms242417540.
2
Top companies and drugs by sales in 2021.
Nat Rev Drug Discov. 2022 Apr;21(4):251. doi: 10.1038/d41573-022-00047-9.
3
Risk of Cancer After Initiation of Targeted Therapies in Patients With Rheumatoid Arthritis and a Prior Cancer: Systematic Review With Meta-Analysis.
Arthritis Care Res (Hoboken). 2023 Feb;75(2):260-271. doi: 10.1002/acr.24784. Epub 2022 Nov 14.
4
Tumor Necrosis Factor Inhibitors and the Risk of Cancer among Older Americans with Rheumatoid Arthritis.
Cancer Epidemiol Biomarkers Prev. 2021 Nov;30(11):2059-2067. doi: 10.1158/1055-9965.EPI-21-0125. Epub 2021 Aug 23.
5
Top companies and drugs by sales in 2020.
Nat Rev Drug Discov. 2021 Apr;20(4):253. doi: 10.1038/d41573-021-00050-6.
6
TNF in the era of immune checkpoint inhibitors: friend or foe?
Nat Rev Rheumatol. 2021 Apr;17(4):213-223. doi: 10.1038/s41584-021-00584-4. Epub 2021 Mar 8.
7
Risk of non-melanoma skin cancer for rheumatoid arthritis patients receiving TNF antagonist: a systematic review and meta-analysis.
Clin Rheumatol. 2020 Mar;39(3):769-778. doi: 10.1007/s10067-019-04865-y. Epub 2019 Dec 10.
8
RoB 2: a revised tool for assessing risk of bias in randomised trials.
BMJ. 2019 Aug 28;366:l4898. doi: 10.1136/bmj.l4898.
9
The TNF Paradox in Cancer Progression and Immunotherapy.
Front Immunol. 2019 Jul 31;10:1818. doi: 10.3389/fimmu.2019.01818. eCollection 2019.
10
Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic Arthritis.
Arthritis Care Res (Hoboken). 2020 Jun;72(6):806-813. doi: 10.1002/acr.23905. Epub 2020 May 15.
Zotero 插件